3 Humongous Healthcare Stocks This Week 2-28-14

  • 5,626 views
Uploaded on

The best-performing healthcare stocks over the last week.

The best-performing healthcare stocks over the last week.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
5,626
On Slideshare
0
From Embeds
0
Number of Embeds
8

Actions

Shares
Downloads
5
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

Transcript

  • 1. 3 Humongous Health-Care Stocks This Week
  • 2. While winter is definitely still here for most of the U.S., some health-care stocks are already generating a lot of heat. Here are the three most humongous health-care stocks of the past week. Source: Wikimedia Commons/
  • 3. InterMune (Nasdaq: ITMN) Shares of the biotech soared 118% this week.
  • 4. Why Intermune more than doubled • It announced phase 3 data for Esbriet. • The drug significantly reduced progression of idiopathic pulmonary fibrosis in patients. • InterMune plans to resubmit the New Drug Application for Esbriet by Q3 of this year.
  • 5. Celladon (Nasdaq: CLDN) Shares of the biotech focusing on cardiovascular disease drugs jumped more than 49% this week.
  • 6. Why Celladon took off • It announced that French drugmaker Servier optioned its novel SERCA2b modulators for treating type 2 diabetes and other metabolic diseases. • Servier gets exclusive global rights outside the U.S. • Celladon also benefited from two analysts initiating coverage this week -- Barclays with an “overweight” rating and Stifel with a “buy” rating.
  • 7. Prana Biotechnology (Nasdaq: PRAN) Shares of the biopharmaceutical company surged nearly 41% higher for the week.
  • 8. Why Prana pushed higher • Investment firm H.C. Wainwright upped its price target for Prana from $20.50 to $33 per share. • The stock experienced a rebound after a big sell-off two weeks ago. • That sell-off stemmed from Summer Street’s doubts about data for Prana’s PBT2, which targets treatment of Huntington’s and Alzheimer’s diseases.
  • 9. Best pick to stay humongous? • Any or all of this week’s humongous stocks could keep moving up. • Celladon gets the nod for most likely to continue its winning ways. • The Servier deal is a huge vote of confidence for the biotech, which only recently went public. • Positive endorsements from major analysts should keep big money flowing into this stock.
  • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!